Streetbeat News

Stock Prices

ACLX

The FDA has lifted the partial clinical hold on Arcellx Inc's iMMagine-1 Phase 2 Clinical Program. Analysts from Needham and William Blair remain optimistic about the long-term therapeutic potential of Arcellx's CART-ddBCMA, despite a delay in the timeline for interim data and regulatory submissions. ACLX shares were up 5.8% at $35.65 on the last check Tuesday.

Portfolio Pulse from Vandana Singh

August 15, 2023 | 6:42 pm

VAPO

Vapotherm's CEO has purchased 300,000 shares of the company at $0.40 per share, according to a Form4 filing.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2023 | 6:30 pm

ADP

Automatic Data Processing (NASDAQ:ADP) has outperformed the market over the past 15 years by 3.6% on an annualized basis, producing an average annual return of 12.27%. If an investor had bought $1000 of ADP stock 15 years ago, it would be worth $5,674.97 today.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 6:30 pm

LULU

Lululemon Athletica (NASDAQ:LULU) has outperformed the market over the past 15 years, producing an average annual return of 27.4%. If an investor had bought $1000 of LULU stock 15 years ago, it would be worth $37,693.97 today.

Portfolio Pulse from Benzinga Insights

August 15, 2023 | 6:30 pm

TCRT

Alaunos Therapeutics Inc (NASDAQ:TCRT) is refocusing its efforts on its hunTR TCR discovery platform and exploring strategic alternatives for the company. This includes winding down its TCR-T Phase 1/2 Library trial and reducing its workforce by 60%. The company has engaged Cantor Fitzgerald & Co as a strategic advisor. Alaunos' shares are down 64.6% at $0.14.

Portfolio Pulse from Vandana Singh

August 15, 2023 | 6:29 pm

AAPL

BABA

INTC

META

MSFT

NVDA

PYPL

UNH

Hedge funds increased their positions in tech stocks in Q2, with Meta Platforms, Microsoft, Nvidia, and Apple seeing the biggest increases. Meta Platforms saw the largest increase by market value, with investment firms increasing their positions by 5.7 million shares. Microsoft saw the next biggest increase, with investment managers adding 2.41 million shares. Amazon, Nvidia, and Apple also saw significant inflows. However, UnitedHealth Group, Alibaba Group, Intel Corp, and PayPal Holdings saw the biggest decreases in overall market value.

Portfolio Pulse from Adam Eckert

August 15, 2023 | 6:29 pm

LOW

Telsey Advisory Group analyst Joseph Feldman reiterated a Market Perform rating on Home Depot Inc (HD) with a $315 price target. Despite a decline in 2Q23 EPS and a tough consumer spending environment, Home Depot's sales exceeded estimates. The analyst also noted that Home Depot's better-than-expected sales could bode well for Lowe's Companies Inc (LOW). HD shares are currently trading higher by 0.55% at $331.7.

Portfolio Pulse from Shivani Kumaresan

August 15, 2023 | 6:26 pm

DCTH

Delcath Systems Inc's stock soared by 90% following the FDA's approval of its HEPZATO KIT for liver-directed treatment in certain adult patients. The approval triggers the second tranche of financing tied to a previously announced PIPE financing, potentially bringing in $34.9 million in additional funding. Further, if the company records at least $10 million in quarterly U.S. revenue from the commercialization of HEPZATO KIT, it could receive up to an additional $24.9 million in funding.

Portfolio Pulse from Vandana Singh

August 15, 2023 | 6:25 pm

ADC

BBY

WMT

Three insiders at Agree Realty Corp. (NYSE:ADC) have recently bought large amounts of company stock, indicating their belief that the stock is undervalued. The purchases were made after a price drop following the company's Q2 2023 earnings announcement. Agree Realty's Q2 revenue was 23.9% higher than the same period in 2022, but missed estimates. The company's year-to-date return is negative 8.79%. Analysts from Stifel and RBC Capital Markets have maintained a positive outlook on Agree Realty, adjusting their price targets slightly.

Portfolio Pulse from Ethan Roberts

August 15, 2023 | 6:20 pm

ODD

KeyBanc Capital Market analyst Scott Schoenhaus initiated coverage on ODDITY Tech Ltd (NASDAQ:ODD) with an Overweight rating and a price target of $60. The analyst sees ODD in the early stages of its growth story, with near-term tailwinds from its ongoing disruption of beauty and wellness end markets and longer-term growth opportunities from its differentiated technology. The company's shares are currently trading lower by 4.73% at $44.16.

Portfolio Pulse from Lekha Gupta

August 15, 2023 | 6:19 pm